Finance

Lists
SLN:NASDAQ
Silence Therapeutics PLC - ADR
$13.77
-1.43%
(-0.20) 1D
Aug 14, 2:03:51 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SLN...
Open
$14.01
High
$14.22
Low
$13.44
Mkt. cap
829.08M
Avg. vol.
1.37M
Volume
453.60K
52-wk high
$17.58
52-wk low
$4.19
EPS
-$1.45
Beta
1.40
Shares outstanding
47.25M
No. of employees
88
Open
$14.01
High
$14.22
Low
$13.44
Mkt. cap
829.08M
Avg. vol.
1.37M
Volume
453.60K
52-wk high
$17.58
52-wk low
$4.19
EPS
-$1.45
Beta
1.40
Shares outstanding
47.25M
No. of employees
88
News stories
From web sources and news partners
Profile
Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London. Wikipedia
About Silence Therapeutics PLC - ADR
CEOCraig A Tooman
Employees88
Founded1994
Headquarters-
SectorBiotechnology
Websitesilence-therapeutics.com
Analyst ratings
Based on 6 analysts giving stock ratings to SLN in the past 3 months
Buy
Buy
5
Hold
0
Sell
1
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for SLN in the last 3 months.
Highest
Current $13.77
$75.00 (+444.66%)
Average
$34.50 (+150.54%)
Lowest
$4.00 (-70.95%)
Analyst
Recommendation
Action
Price target
Projected
Date
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$75.00
+444.7%
08/14/2026
Michael Ulz
Morgan Stanley
Buy
Reiterated
$32.00
+132.4%
08/11/2026
Keay Nakae
Chardan Capital
Buy
Maintained
$27.00
+96.1%
08/10/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
08/10/2026
Richard Law CFA
Goldman Sachs
Sell
Maintained
$4.00
-71%
07/27/2026
Prakhar Agrawal
Cantor Fitzgerald
Buy
Initiated
-
-
06/24/2026
Previous reportsAll values in GBP
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
159.00K
34.00K
422.00K
-
Cost of goods sold
64.00K
12.00K
11.00K
-
Cost of revenue
64.00K
12.00K
11.00K
-
Research and development expenses
17.96M
8.92M
8.43M
8.37M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.80M
3.73M
7.03M
4.72M
Operating expense
23.76M
12.65M
15.46M
13.09M
Total operating expenses
23.82M
12.66M
15.47M
13.09M
Operating income
-23.66M
-12.63M
-15.05M
-13.09M
Other non operating income
770.00K
865.00K
571.00K
669.00K
EBT including unusual items
-20.96M
-11.77M
-14.96M
-12.27M
EBT excluding unusual items
-20.96M
-11.77M
-14.96M
-12.27M
Income tax expense
1.00K
-
-
1.00K
Effective tax rate
-
-
-
-0.01%
Other operating expenses
-
-
-
-
Net income
-20.96M
-11.77M
-14.96M
-12.27M
Net profit margin
-13,181.13%
-34,617.65%
-3,544.31%
-
Earnings per share
-0.15
-0.27
-0.33
-0.27
Interest and investment income
-
15.00K
-
-
Interest expense
-
-
-
-
Net interest expenses
-
15.00K
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-23.50M
-12.52M
-14.94M
-12.98M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps